Synthesis of immunogens improves immune recognition of tumor-associated MUC1 glycopeptides, suggesting a new vaccination strategy.
A generalizable semisynthetic vaccine approach to increase antigen presentation and immune recognition of poorly immunogenic tumor-associated MUC1 glycopeptides.
No takes yet. Share an insight, caveat, or question.
Pifferi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: